Trial reportThe American journal of tropical medicine and hygiene2010
A controlled, randomized-blinded clinical trial to assess the efficacy of a nitric oxide releasing patch in the treatment of cutaneous leishmaniasis by Leishmania (V.) panamensis.
Trial report in The American journal of tropical medicine and hygiene, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Interventions for American cutaneous and mucocutaneous leishmaniasis.The Cochrane database of systematic reviews · 2020Pooled it
- Efficacy of cryotherapy for the treatment of cutaneous leishmaniasis: meta-analyses of clinical trials.BMC infectious diseases · 2016Pooled it
- Interventions for American cutaneous and mucocutaneous leishmaniasis: a systematic review update.PloS one · 2013Pooled it
- A phase II study to evaluate the safety and efficacy of topical 3% amphotericin B cream (Anfoleish) for the treatment of uncomplicated cutaneous leishmaniasis in Colombia.PLoS neglected tropical diseases · 2018Trial
- Randomized, double-blinded, phase 2 trial of WR 279,396 (paromomycin and gentamicin) for cutaneous leishmaniasis in Panama.The American journal of tropical medicine and hygiene · 2013Trial
- Electrospun nanofibers: Focus on local therapeutic delivery targeting infectious disease.Journal of drug delivery science and technology · 2025Article
- Cutaneous leishmaniasis treatment and therapeutic outcomes in special populations: A collaborative retrospective study.PLoS neglected tropical diseases · 2023Article
- Current and future strategies against cutaneous parasites.Pharmaceutical research · 2022Review
- Synthetic, Natural, and Semisynthetic Polymer Carriers for Controlled Nitric Oxide Release in Dermal Applications: A Review.Polymers · 2021Review
- Application of laser for treatment of cutaneous leishmaniasis: a review of literature.Lasers in medical science · 2020Review
- Application of electrospun fibers for female reproductive health.Drug delivery and translational research · 2017Review
- In pursuit of functional electrospun materials for clinical applications in humans.Therapeutic delivery · 2016Review
- Article
- Leishmanicidal activities of novel synthetic furoxan and benzofuroxan derivatives.Antimicrobial agents and chemotherapy · 2014Article
- Review
- Synthetic and degradable patches: an emerging solution for rotator cuff repair.International journal of experimental pathology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A topical nanofiber nitric oxide (NO) releasing patch ( approximately 3.5 mumol NO/cm(2)/day for 20 days, NOP) was compared with intramuscular meglumine antimoniate (Glucantime, 20 mg/kg/day for 20 days) for the treatment of cutaneous leishmaniasis (CL) caused by Leishmania (V.) panamensis in Santander and Tolima, Colombia. A double-blind, randomized, placebo-controlled, clinical trial was conducted to determine whether the NOP is as effective as Glucantime for the treatment of CL. Patients were randomly assigned to Glucantime and placebo patches or NOP and placebo of Glucantime. The cure rates after a 3-month follow-up were 94.8% for the group that received Glucantime compared with 37.1% in the NOP group. Despite the lower efficacy of the NOP versus Glucantime, a significantly lower frequency of non-serious adverse events and a reduced variation in serum markers were observed in patients treated with NOP. Treatment of CL with NOP resulted in a lower effectiveness compared with Glucantime; however, the low frequency of adverse events and the facility of topic administration justify the development of new generations of NOP systems for the treatment of CL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.